OBiO Technology

OBiO Technology is a pioneering Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) in gene and cell therapy, offering comprehensive solutions.

With years of dedicated effort, OBiO has developed an integrated process development system, supported by a flexible cGMP manufacturing platform, a comprehensive quality system, and efficient project management. Our state-of-the-art 77,000m2 (830,000 ft2) facility for Global Supply ensures high-quality CDMO services across preclinical, IND, clinical, and commercial stages to meet global demand.

Guided by our mission "Enable Gene Therapy for Better Lives," we deliver top-tier services worldwide, from laboratory to clinic. We specialize in vectorology studies, functional genomics, and process and analytics development, ensuring Investigational New Drug (IND) readiness and supporting all clinical and commercial manufacturing phases.

Our expertise includes plasmids, mRNA, AAV, LVV, Ad viral vectors, cell therapy (CAR-T, NK, Treg, iPSCs), exosomes, and cutting-edge technologies like inducible viral vector packaging, ultralow endotoxin processes, and AAVneO for tissue-specific AAV variants.